Environmental and Endogenous Peroxisome Proliferator-Activated Receptor γ Agonists Induce Bone Marrow B Cell Growth Arrest and Apoptosis: Interactions between Mono(2-ethylhexyl)phthalate, 9-cis-Retinoic Acid, and 15-Deoxy-Δ12,14-prostaglandin J₂₁

Jennifer J. Schlezinger,2* Gregory J. Howard,† Christopher H. Hurst,‡ Jessica K. Emberley,* David J. Waxman,† Thomas Webster,* and David H. Sherr*”

The common commercial use of phthalate esters has resulted in significant human exposure to these bioactive compounds. The facts that phthalate ester metabolites, like endogenous PGs, are peroxisome proliferator-activated receptor (PPAR) agonists, and that PPARγ agonists induce lymphocyte apoptosis suggest that phthalate esters are immunosuppressants that could act together with PGs to modulate early B cell development. In this study we examined the effects of a metabolite of one environmental phthalate, mono(2-ethylhexyl)phthalate (MEHP), and 15-deoxy-Δ12,14-PGJ₂ (15d-PGJ₂), on developing B cells. MEHP inhibited [³H]thymidine incorporation by primary murine bone marrow B cells and a nontransformed murine pro/pre-B cell line (BU-11). Cotreatment with a retinoid X receptor α ligand, 9-cis-retinoic acid, decreased [³H]thymidine incorporation synergistically, thereby implicating activation of a PPARγ-retinoid X receptor α complex. These results were similar to those obtained with the natural PPARγ ligand 15d-PGJ₂. At moderate MEHP concentrations (25 or 100 μM for primary pro-B cells and a pro/pre-B cell line, respectively), inhibition of [³H]thymidine incorporation resulted primarily from apoptosis induction, whereas at lower concentrations, the inhibition probably reflected growth arrest without apoptosis. Cotreatment of bone marrow B cells with 15d-PGJ₂ and MEHP significantly enhanced the inhibition of [³H]thymidine incorporation seen with MEHP alone, potentially mimicking exposure in the bone marrow microenvironment where PG concentrations are high. Finally, MEHP- and 15d-PGJ₂-induced death does not result from a decrease in NF-kB activation. These data demonstrate that environmental phthalates can cooperate with an endogenous ligand, 15d-PGJ₂, to inhibit proliferation of and induce apoptosis in developing bone marrow B cells, potentially via PPARγ activation. The Journal of Immunology, 2004, 173: 3165–3177.

P

hthalate esters are ubiquitous environmental contaminants that are produced for a variety of common industrial and commercial purposes. Worldwide, >18 billion pounds of phthalates are produced yearly, mainly for use as plasticizers in polyvinyl chloride products, such as car seats, toys, and bloodbags (1, 2). The annual global production of di(2-ethylhexyl)phthalate (DEHP), the main plasticizer used in the production of polyvinyl chloride, is 3–4 million tons (1). The average daily human exposure to DEHP and its metabolite, mono(2-ethylhexyl)phthalate (MEHP), has been estimated to be 0.6–0.7 μg/kg/day and may be as high as 30–40 μg/kg/day in occupationally exposed populations (2–5). Exposure to DEHP from a blood transfusion alone can be as high as 3-4 mg/kg for an adult weighing 70 kg (6), and concentrations of DEHP in blood can range from 50–350 μM (7). DEHP exposure alone has been linked to hepatocarcinogenesis (8) and ovarian (9), testicular (10, 11), and developmental (12) toxicity.

Recently, MEHP as well as many other phthalate esters were shown to be agonists for peroxisome proliferator-activated receptor (PPARs) (13–16). PPARs are members of a nuclear hormone receptor superfamily and are comprised of three subtypes, α, δ, and γ. After ligand binding, the PPAR forms a heterodimeric complex with the retinoid X receptor α (RXRα), initiating a conformational change that results in the dissociation of corepressors, the association of coactivators, and receptor complex binding to PPAR-response elements (5′-AACTAGGNC A AGGTCA-3′; the consensus sequences are underlined) in genes such as acyl-CoA oxidase and cytochrome P450 4A (17). Transcriptional activity may be enhanced in the presence of ligands for both PPAR and RXRα (18–21). It has been assumed, but not proven, that this enhancement is synergistic rather than additive.

PPARαs are expressed highly in metabolically active tissues, such as liver, heart, and kidney (22), and recently has been found to be expressed in myeloid and lymphoid cells (23). PPARα regulates the uptake, activation, and β-oxidation of fatty acids (22). Its agonists induce peroxisome proliferation, hepatomegaly, and hepatothe...
carcinoma (as reviewed in Ref. 24) as well as splenic and thymic atrophy (25) in rodents in a PPARα-dependent manner. MEHP, the active metabolite of DEHP, transcriptionally activates PPARα (15, 16). However, PPARα activation alone cannot explain the renal, testicular, or reproductive toxicity or teratogenicity of DEHP, because PPARα-null and wild-type mice are equally susceptible to these DEHP-induced toxic effects (8, 11, 26, 27).

PPARγ is expressed highly in the immune system (28, 29), particularly in mouse and human tissues that contain high percentages of B cells, such as spleen, lymph nodes, and bone marrow (23, 28, 30–32). PPARγ plays an important role not only in regulating adipocyte differentiation (33) and insulin responsiveness (34), but also in immune function, particularly in macrophage inflammatory responses (35–37), T cell activation (38, 39), and dendritic cell maturation (40). Notably, a reduction of PPARγ expression in haploinsufficient mice increases B cell proliferative responses (41), suggesting an important role for this receptor in B cell growth regulation. MEHP transcriptionally activates PPARγ (15, 16) and stimulates adipogenesis, a PPARγ-dependent process (14), suggesting a molecular mechanism through which environmental phthalates may compromise B cell function.

PPARγ agonists, including 15-deoxy-D12,14-PGJ2 (15d-PGJ2) and glitazone drugs, induce apoptosis in monocytes (37), T cells (42), and B cells (30, 31). Treatment of murine primary bone marrow B cells, a nontransformed murine pro/pre-B cell line, or a transformed murine immature B cell line with drugs that target PPARγ (ciglitazone and GW347845X) induces PPARγ-peroxisome proliferator response element (PPRE) binding, NF-κB up-regulation, and rapid apoptosis (31). Cotreatment with 9-cis-retinoic acid (9-cis-RA) decreases the PPARγ agonist dose required to activate NF-κB and induce apoptosis. These data suggest that activation of PPARγ-RXR initiates a potent apoptotic signaling cascade in B cells through PPARγ activation and possibly NF-κB regulation. However, they do not reveal how environmental PPARγ ligands may affect developing lymphocytes, nor do they address the consequences of coactivation of PPARγ with environmental and endogenous agonists such as MEHP and 15d-PGJ2, respectively.

The facts that common environmental phthalate ester metabolites are PPAR agonists and that PPARγ agonists induce lymphocyte apoptosis suggest that environmental phthalate esters may be important immunosuppressants. Furthermore, the effect of PPARγ haploinsufficiency on B cell proliferation suggests PPARγ agonist regulation of B cell growth as well as death. Finally, the high bone marrow concentrations of PGD2, the precursor to the potent PPARγ agonist, 15d-PGJ2 (43–45), may lower the threshold of B cell responses to environmental PPARγ agonists. Therefore, we determined whether MEHP, a metabolite of the ubiquitous phthalate DEHP, adversely affects the developing immune system by inducing bone marrow B cell apoptosis and/or growth arrest and whether 15d-PGJ2 exacerbates these putative effects. The data presented show that MEHP inhibits B cell proliferation and induces apoptosis at relatively low doses, potentially via a signaling cascade involving PPARγ, and that the developing lymphoid system, like many developing organ systems, is particularly susceptible to a spectrum of environmental chemicals, including phthalates.

Materials and Methods

Reagents

9-Cis-RA was obtained from Biomol (Plymouth Meeting, PA). The PPARγ-specific Ab was purchased from Calbiochem (San Diego, CA). 15d-PGJ2 was obtained from Cayman Chemical (Ann Arbor, MI). Phasmo- cin was purchased from InvivoGen (San Diego, CA). Marine rIL-7 was obtained from Research Diagnostics (Flanders, NJ). The NF-κB and p27Kip1-specific Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Troglitazone was obtained from the Sankyo (Tokyo, Japan). Propidium iodide and Protease Inhibitor Cocktail for Mammalian Cells were obtained from Sigma-Aldrich (St. Louis, MO). MEHP was purchased from TCI America (Portland, OR). All other reagents were obtained from Fisher Scientific (Suwanee, GA).

Plasmids

The mouse PPARγ expression plasmid pSV-Sport1-PPARγ (46) was provided by J. K. Reddy (Northwestern University Medical School, Chicago, IL). The firefly luciferase (Luc) reporter plasmid pHDX-3-luc contains three copies of a PPRE derived from the rat enoyl CoA hydratase/3-hydroxacyl CoA oxidase promoter (nt –2956 to –2919) cloned into carbamoyl-phosphate synthetase/Luc reporter (47) and was obtained from Dr. J. Capone (McMaster University, Ontario, Canada). The reporter plasmid pLuc-4A6–880, containing 880 nt of the 5′-flanking DNA of the rabbit CYP4A4 gene cloned into p19Luc was provided by Dr. E. Johnson (The Scripps Research Institute, La Jolla, CA). The Renilla luciferase reporter plasmid pRL-CMV was purchased from Promega (Madison, WI).

Bone marrow B cell isolation

B cells were isolated from the bone marrow of 4- to 6-wk-old C57BL/6 male mice and cultured in RPMI 1640 containing 10% FBS, 1-glutamine, penicillin/streptomycin, 2-ME, and 16 ng/ml murine rIL-7 for 5–7 days by the method of Tze et al. (48). Before experimentation, these cells (>80% B220+/CD43−) were purified further using anti-B220 microbeads and a magnetic column (MACS, Miltenyi Biotec, Auburn, CA). After purification, 95.1 ± 0.5% of the cells were B220+/CD43−.

Cell lines

The stromal cell-dependent, C57BL/6-derived BU-11 cell line has been characterized previously (49). BU-11 cells represent B cells at the transition between the pro- and early pre-B cell stages as they are CD43+/B220−/IgM+ with rearranged IgH chain genes (50). BMS2 is a culture dish-adherent, cloned bone marrow stromal cell line that supports BU-11 cell growth (51). Stoids of BU-11 cells were maintained on BMS2 cell monolayers in an equal mixture of DMEM and RPMI 1640 medium with 5% FBS, plasmocin, 1-glutamine, and 2-ME. For experiments, BU-11 cells were plated without BMS2 in the presence of murine rIL-7 (16 ng/ml). All cultures were maintained at 37°C in a humidified, 7.5% CO2 atmosphere. COS-1 cells (American Type Culture Collection, Manassas, VA) were grown in DMEM containing 10% FBS (Sigma-Aldrich) and 50 U/ml penicillin/streptomycin. COS-1 Golgi Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

[3H]Thymidine incorporation

Primary bone marrow B cells or BU-11 cells were cultured in 96-well plates in medium containing 5% FBS and treated with ethanol (vehicle; final concentration, 0.5%), MEHP (10–200 μM), 15d-PGJ2 (0.5–20 μM) and/or 9-cis-RA (10 μM) for 24 h. [3H]-labeled thymidine (1 μCi/well) was added, and the incubation was continued for 24 h. Cells were harvested using a cell harvester (PhD, Cambridge, MA). The [3H]thymidine retained on the filter was detected using a scintillation counter (Beckman Coulter, Fullerton, CA).

Analysis of apoptosis

For propidium iodide (PI) staining, primary bone marrow B cells or BU-11 cells were cultured in 24-well plates in medium containing 5% FBS and were treated with ethanol (vehicle; final concentration, 0.1%), MEHP (50–200 μM), 15d-PGJ2 (0.5–10 μM), and/or 9-cis-RA (10–20 μM) for 8–24 h. Cells were harvested by gentle pipetting; washed once with cold PBS containing 5% FBS and 10 μM azide; resuspended in 0.25 ml of hypotonic buffer containing 50 μg/ml PI, 1% sodium citrate, and 0.1% Triton X-100; and analyzed on a FACScan flow cytometer (BD Biosciences, Mountain View, CA). For apoptosis studies, cells were monitored with FL-2 output in the log mode. The percentage of cells undergoing apoptosis was determined to be those with a weaker PI fluorescence than cells in the G1/G0 phase of the cell cycle (49).

For determination of DNA fragmentation, BU-11 cells were cultured in T25 flasks in medium containing 5% FBS and treated with ethanol (vehicle; final concentration, 0.1%), MEHP (50–200 μM), 15d-PGJ2 (2–10 μM), and/or 9-cis-RA (10–20 μM) for 24 h. DNA was isolated and processed as previously described (31). Before loading on a 1.5% agarose gel, the DNA was quantified and treated with 10 μg/ml RNase A at 37°C for 10 min. DNA was visualized using ethidium bromide staining.
Analysis of cell cycle arrest

Cells were treated as described above for 48 h and stained with PI. Stained cells were analyzed by flow cytometry with FL-2 output in the linear mode.

The expression of p27\(^{kip1}\) was determined by Western blotting. BU-11 cells were cultured in T75 flasks in medium containing 5% FBS and treated with ethanol (vehicle; final concentration, 0.1%), MEHP (50–100 \(\mu\)M), 15d-PGJ\(_2\) (0.5–2 \(\mu\)M), and/or 9-cis-RA (10 \(\mu\)M) for 48 h. Whole cell lysates were prepared as described previously (52). Protein concentrations were determined by the Bradford method. Proteins (30 \(\mu\)g) were resolved on 12% gels, transferred to a 0.2-\(\mu\)m nitrocellulose membrane, and incubated with polyclonal p27\(^{kip1}\)-specific Ab (Sigma-Aldrich) and analyzed as described above. An untreated BU-11 cell control was run with each Western blot, and the data from experimental samples were normalized by dividing by the density measured in the untreated control.

Analysis of chemical interactions; additive vs synergistic effects

BU-11 cells were cultured in 96-well plates in medium containing 5% FBS; treated with ethanol (vehicle; final concentration, 0.5%), MEHP (25–100 \(\mu\)M), 15d-PGJ\(_2\) (0.5–2.5 \(\mu\)M), and/or 9-cis-RA (1–10 \(\mu\)M) for 48 h; and assayed for \(^3\)H]thymidine incorporation as described above. The method of isoboles was used to analyze combinations of MEHP with 9-cis-RA or 15d-PGJ\(_2\) for synergistic effects (53, 54). The dose of \(x\), plotted on one horizontal axis, \(x\), on the other horizontal axis, and the response on the vertical (\(y\)) axis. The dose-response curve for each individual compound lies on the axes. The contours of this surface are called isoboles and denote curves of equal response. The shape of the isoboles provides qualitative information about interactions. Isoboles that are approximately linear with a negative slope suggest an additive effect, using the definition of concentration or Loewe additivity (53, 54). Isoboles that bow toward the origin indicate a greater response than that suggested by additivity, i.e., synergy. The contour plots were created in the R statistical environment (version 1.7.1 for Windows XP; R Foundation, Vienna, Austria; www.r-project.org).

Transient transfections

COS-1 cells were cultured in a 48-well plate and transfected 24 h later using FuGene 6 transfection reagent (Roche, Mannheim, Germany) as previously described (16). The transfection mixture contained 90 ng of luciferase reporter plasmid, 5 ng of PPAR\(\gamma\) expression plasmid, and 1 ng of pRL-CMV per well in a volume of 15 \(\mu\)l of DMEM containing 0.3 \(\mu\)l of FuGene 6. Salmon sperm DNA (Stratagene, La Jolla, CA) was added as carrier DNA to give a total of 250 ng of DNA/well. Culture medium was replaced 16–18 h later with serum-free DMEM containing vehicle (DMSO; final concentration, 0.5%), MEHP (20 \(\mu\)M), 15d-PGJ\(_2\) (1–15 \(\mu\)M), or trichloroethane (3 \(\mu\)M). After treatment for 24 h, cells were lysed by incubation at 4°C in 200 \(\mu\)l of passive lysis buffer (Promega) for 20 min. Firefly and Renilla luciferase activities were measured in cell lysates using a dual reporter assay system (Promega) and a Monolight 2010 luminometer (Analytical Luminescence Laboratory, San Diego, CA). Luciferase activity values were normalized for transfection efficiency using Renilla luciferase activity assayed in the same cell lysates (firefly luciferase/Renilla luciferase).

EMSA

BU-11 cells were cultured in T75 flasks in medium containing 5% FBS and treated with vehicle (ethanol or DMSO; final concentration, 0.1%), MEHP (100–200 \(\mu\)M), or 15d-PGJ\(_2\) (2.5–5 \(\mu\)M) for 2–24 h. Cells were collected and washed in PBS. Nuclear proteins were extracted as described previously (31).

For determination of PPAR\(\gamma\)-DNA binding, a double-stranded oligonucleotide containing the PPRE from the acyl-CoA oxidase gene (\(5^{'-}\)GTCCGACAGGGGACCGAACAAGGTCCATGCGGCCGTACG3’; the consensus sequences are underlined) was used (44). PPAR\(\gamma\) binds to this site with significantly greater affinity than PPAR\(\alpha\) (55). The DNA probe was end-labeled using T4 polynucleotide kinase (Promega) and [\(^{32}\)P]ATP and was purified using a Centriplus-20 column (Pierce Separations, Adelphia, NJ). EMSAs were performed as follows. The \(3^{'-}\)P-labeled DNA (0.5 ng, 100,000 cpm) and 4 \(\mu\)g of nuclear protein were combined with buffer (final concentrations: 20 mM HEPES (pH 8), 0.2 mM EDTA, 60 mM sodium chloride, 0.1% Nonidet P-40, 1 mM DTT, and 10% glycerol) and poly(dI-dC) (1 \(\mu\)g) in a final volume of 20 \(\mu\)l. The mixture was incubated at room temperature for 30 min. Polyacrylamide gels (16 cm, 5%) were prerun at 200 V for 30 min. Mixtures were electrophoresed at 200 V for 1.5 h in 0.5x TBE (final concentrations: 44 mM Tris-base (pH 8), 44 mM boric acid, and 0.8 mM EDTA). The gels were dried and exposed to film. The specificity of the shifted bands was determined by including an Ab specific for PPAR\(\gamma\) (Calbiochem, La Jolla, CA; 516555) or by including 100x cold oligonucleotides containing the PPRE from the acyl-CoA oxidase gene (see above) or an unrelated site (5’-GAGCCCCGAATGACCTGCGGATGATTTA3’).

For determination of NF-\(\kappa\)B activation, a double-stranded oligonucleotide containing the NF-\(\kappa\)B binding site from the upstream regulatory element of c-myc (5’-GATCCAAAGGTTCCGGTACCCACG-3’; the consensus sequence is underlined) was used (56). The DNA probe was end-labeled and purified as described above. EMSAs were performed as follows. The \(5^{'-}\)-labeled DNA (0.5 ng, 50,000 cpm) and 2 \(\mu\)g of nuclear protein were combined with buffer (final concentrations: 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 100 mM sodium chloride, 0.5 mM magnesium chloride, 1 mM DTT, 20 \(\mu\)g BSA, 10% glycerol, and 0.5% Triton X-100) and poly(dI-dC) (1 \(\mu\)g) in a final volume of 20 \(\mu\)l. The mixture was incubated at room temperature for 30 min. The gel was run as described above, dried, and exposed to film. For quantification, the gels were analyzed on a PhosphorImager (Molecular Dynamics). The identity of the NF-\(\kappa\)B subunits was determined by including Abs specific for p50 (sc-114), p52 (sc-848), Rel A (sc-372), or c-Rel (sc-71).

Statistics

Statistical analyses were performed with StatView (SAS Institute, Cary, NC). Data from a minimum of three experiments are presented as the mean ± SE. Student’s t test and one-factor ANOVAs were used to analyze the data. For the ANOVAs, Dunnett’s or Fisher’s protected least significant difference (PLSD) multiple comparisons tests was used to determine significant differences.

Results

MEHP reduces \[^3\]H\]thymidine incorporation and induces apoptosis in primary bone marrow B lymphocytes

Previous studies demonstrated that B cells in early stages of development undergo apoptosis when exposed to synthetic PPAR\(\gamma\) agonist drugs (30). Given this observation, the presence of a natural PPAR\(\gamma\) agonist in the bone marrow (i.e., 15d-PGJ\(_2\)), the ability of environmental phthalates to activate PPAR\(\gamma\) (13–16), and the relatively high human exposure to environmental phthalate esters, we investigated the potential for environmental phthalate esters to affect developing B lymphocytes. Models of early bone marrow B cell development were chosen because of the increased sensitivity of developing organs in general to environmental chemicals (49, 57, 58).

Primary bone marrow B cells were exposed to increasing concentrations of MEHP. \[^3\]H\]thymidine incorporation, a measure of cell proliferation and/or survival, was assessed 48 h later. In primary bone marrow B220\(^{+}\)/CD43\(^{+}\) B cells, MEHP caused a significant reduction in \[^3\]H\]thymidine incorporation at concentrations as low as 10 \(\mu\)M, whereas higher concentrations caused correspondingly larger decreases in \[^3\]H\]thymidine incorporation (Fig. 1A). To evaluate the potential for MEHP to induce apoptosis in primary bone marrow B cells, cells were treated at a range of MEHP concentrations (10–150 \(\mu\)M) for 16 h, stained with PI, and analyzed for the percentage of cells with a sub\(G_0//G_1\) DNA content. Apoptosis was readily detected by flow cytometry after exposure to MEHP (Fig. 1B). Treatment with doses as low as 25 \(\mu\)M MEHP consistently induced apoptosis in a significant fraction of these B220\(^{+}\)/CD43\(^{+}\) B cells (Fig. 1C). The percentage of apoptotic cells increased with concentrations of MEHP, reaching ~35% above background at 150 \(\mu\)M. These data are consistent with those obtained with PPAR\(\gamma\) agonist drugs and suggest that environmental phthalates are similarly immunotoxic.

MEHP reduces \[^3\]H\]thymidine incorporation and induces cell cycle arrest in a pro/pre-B cell line

A nontransformed, bone marrow stromal cell-dependent pro/pre-B cell line, BU-11, was used to confirm and extend studies on the
effects of MEHP on developing B lymphocytes. First, BU-11 cells were exposed to increasing concentrations of MEHP, and [3H]thymidine incorporation was assessed 48 h later to compare the responses of this cell line to those seen with primary B cells. As with primary bone marrow B cells, MEHP caused a significant reduction in [3H]thymidine incorporation in BU-11 pro/pre-B cells (Fig. 2, open histograms), although BU-11 cells were less sensitive to the MEHP-dependent decrease in [3H]thymidine incorporation than primary bone marrow B cells.

If inhibition of [3H]thymidine incorporation were due to activation of PPARγ, it would be predicted that simultaneous activation of its dimerization partner, RXRα, would enhance the biological effect of MEHP. For example, cotreatment of cells with PPARγ and RXRα agonists results in enhanced PPRE-dependent transcription (18–21). Therefore, we tested the effect of MEHP and 9-cis-RA cotreatment on [3H]thymidine incorporation by BU-11 cells. [3H]thymidine incorporation was reduced significantly in BU-11 cells by treatment with 9-cis-RA (10 μM) alone (Fig. 2, first solid histogram). Importantly, cotreatment with 10 μM 9-cis-RA and MEHP potentiated the reduction of [3H]thymidine incorporation by BU-11 cells (Fig. 2, solid histograms) at all MEHP concentrations.

A reduction in [3H]thymidine incorporation can be attributable to a diminution of DNA synthesis (i.e., proliferation) and/or an increase in cell death. To distinguish between these two possibilities, BU-11 cells were stained with PI and analyzed by flow cytometry for the percentage of cells expressing a subG0/G1 fluorescence peak (i.e., apoptotic cells) and for the percentage of cells expressing S/G2/M levels of DNA (i.e., dividing cells).

To evaluate the potential for MEHP to induce apoptosis, BU-11 cells were treated with 50–200 μM MEHP for 24 h. BU-11 cells exhibited a relatively low level of background apoptosis (<7%);
Treatment with 150 or 200 μM MEHP consistently induced apoptosis in a significant fraction of these pro/pre-B cells (~20 and ~40%, respectively). As expected, DNA fragmentation, a hallmark of apoptosis, was readily demonstrated in BU-11 cells after a 24-h exposure to 150–200 μM MEHP (Fig. 3C, lanes 5 and 7). Apoptosis also was confirmed by detection of poly(ADP-ribose) polymerase cleavage, an activity of effector caspase 3, after exposure to 150–200 μM MEHP (data not shown).

To ascertain the contribution of RXRα to MEHP-induced apoptosis, BU-11 cells were treated with MEHP (50–200 μM) with or without 10 or 20 μM 9-cis-RA for 24 h. Addition of 10 μM 9-cis-RA to BU-11 cell cultures did not affect BU-11 cell viability (Fig. 3, A and B). In contrast, cotreatment with 20 μM 9-cis-RA and a suboptimal dose of MEHP, e.g., 100 μM, increased the incidence of apoptosis even more (Fig. 3, A and B). The enhancement of apoptosis by 9-cis-RA in combination with MEHP also was reflected in DNA ladder formation (Fig. 3C, lanes 5 and 6). These data are consistent with a role for the PPARγ-RXRα heterodimer in MEHP-mediated pro/pre-B cell apoptosis signaling.

It was noted that BU-11 cell apoptosis could not be detected after exposure to 100 μM MEHP (Fig. 3B and C), a concentration at which inhibition of [3H]thymidine incorporation could be demonstrated (Fig. 2). Similarly, in primary bone marrow B cells, [3H]thymidine incorporation was reduced significantly at concentrations below those at which apoptosis was evident (e.g., 10 μM; Fig. 1, A and C). These results suggest that MEHP induces growth arrest rather than apoptosis at low concentrations. To evaluate the potential for MEHP to induce growth arrest and thereby to reduce [3H]thymidine incorporation, BU-11 cells were exposed to low concentrations of MEHP (50–100 μM) with and without 10 μM 9-cis-RA for 48 h.

A significant decrease in the number of cells in S/G2/M was observed after treatment with 100 μM, but not 50 μM, MEHP (Fig. 4A, open histograms). Therefore, the reduction in [3H]thymidine incorporation at 100 μM MEHP is probably due to growth arrest before or during the DNA synthesis phase. This decrease in

**FIGURE 3.** MEHP induces apoptosis in pro/pre-B cells. Suspension cultures of BU-11 cells were treated with ethanol (vehicle, 0.1%), MEHP (50–200 μM), and/or 9-cis-RA (10–20 μM) for 24 h. Apoptosis assays were performed as described in Materials and Methods. A, Formation of a subG0/G1 population after PI staining. Data are representative of four experiments. B, Quantification of the subG0/G1 population. Data are presented as the mean ± SE from four experiments. *, Statistically different from vehicle- and 9-cis-RA-treated (p < 0.01, by ANOVA and Fisher’s PLSD test). +, Statistically different from vehicle-, 9-cis-RA-, and MEHP-treated at the same dose (p < 0.01, by ANOVA and Fisher’s PLSD test). C, Formation of DNA ladders. Data are representative of three experiments.
the percentage of cycling cells was even more profound upon inclusion of 9-cis-RA (Fig. 4A, solid histograms). Although 100 μM 9-cis-RA or 100 μM MEHP alone reduced the percentage of cycling cells by 7–8%, the effects of treating cells with 10 μM 9-cis-RA together with 100 μM MEHP appeared more than additive (i.e., a 22% reduction in the percentage of cycling cells). Therefore, a PPARγ-RXRα complex appears to participate in growth arrest as it does in apoptosis induction.

The p27Kip1 protein is a cyclin-dependent kinase inhibitor that blocks cyclin E/cyclin-dependent kinase 2, a cyclin that controls passage through G1 into S phase (59). To begin to assess the mechanisms by which MEHP and 9-cis-RA induce cell cycle arrest, BU-11 cells were exposed to low concentrations of MEHP (50–100 μM) with and without 10 μM 9-cis-RA for 48 h. Whole-cell lysates were examined for p27Kip1 expression by Western blotting. Treatment with either 100 μM MEHP or 9-cis-RA alone resulted in a modest, but statistically significant, increase in p27Kip1 (Fig. 4B). As with the other readouts, the effects of 50 μM MEHP added together with 9-cis-RA were more profound than those with either agent alone (4.5-fold; p < 0.05). The results are consistent with the hypothesis that MEHP- and/or 9-cis-RA-mediated growth arrest involves the up-regulation of the cell cycle inhibitor p27Kip1.

15d-PGJ2, a natural PPARγ ligand in the bone marrow, reduces [3H]thymidine incorporation by inducing apoptosis and cell cycle arrest in pro/pre-B lymphocytes

15d-PGJ2 is a PPARγ agonist (44) whose precursor PGD2 is found in high concentrations in the bone marrow microenvironment (43, 45), suggesting its role in lymphocyte development. As such, it may potentiate the toxic effects of environmental PPARγ agonists. To test this possibility, the ability of 15d-PGJ2 to affect pro/pre-B cell growth and survival, either alone or in combination with MEHP, was evaluated.

BU-11 cells were exposed to increasing concentrations of 15d-PGJ2 and 9-cis-RA for 48 h, and [3H]thymidine incorporation was assessed. 15d-PGJ2 caused a >90% reduction in [3H]thymidine incorporation at concentrations as low as 5 μM (Fig. 5A). [3H]thymidine incorporation was inhibited completely at ≥10 μM 15d-PGJ2. Similarly, 5 μM 15d-PGJ2 induced a significant increase in a subG0/G1 fluorescence peak after an 8-h exposure (vehicle, 10 ± 1%; 15d-PGJ2, 62 ± 1%; p < 0.01) and significant DNA fragmentation after a 24-h exposure (Fig. 5B, lane 5). It is important to note that 2 μM 15d-PGJ2 did not significantly affect either [3H]thymidine incorporation or DNA fragmentation. These results
indicate that 15d-PGJ₂ is a potent inhibitor of pro/pre-B cell [³H]thymidine uptake and that this decrease in [³H]thymidine uptake is due, at least at concentrations ≥5 μM, to apoptosis induction.

Neither 10 μM 9-cis-RA nor 0.5 μM 15d-PGJ₂ had an effect on [³H]thymidine incorporation when either agent was added alone (Fig. 5C). However, a combination of 10 μM 9-cis-RA and 0.5 μM 15d-PGJ₂ significantly reduced [³H]thymidine incorporation (Fig. 5C, solid histograms). Indeed, the combinatorial effect of these respective PPARγ and RXRα agonists was most evident when adding 2 μM 15d-PGJ₂ together with 10 μM 9-cis-RA. However, no increase in DNA ladder formation was seen when combining 2 μM 15d-PGJ₂ and 10 μM 9-cis-RA (Fig. 5B), suggesting that the significant decrease in [³H]thymidine incorporation was probably due to cell cycle arrest. Similarly, although 1–2 μM 15d-PGJ₂ or 10 μM 9-cis-RA alone increased p27kip1 expression, the combination of these respective PPARγ and RXRα agonists resulted in a significant effect with regard to p27kip1 expression (an 18.4 ± 4.0-fold increase; p < 0.05; Fig. 5D). Collectively, these data indicate that this natural PPARγ ligand induces p27kip1 expression concomitant with growth arrest at concentrations lower than those capable of inducing apoptosis (i.e., ≤2 μM) and that this effect is enhanced significantly by coactivation of a PPARγ dimerization partner, i.e., RXRα.

To determine whether 15d-PGJ₂ potentiates the activity of an environmental PPARγ agonist, BU-11 cells were treated with 100 μM MEHP, i.e., a suboptimal concentration that induces a low level of growth arrest (Fig. 4), but no apoptosis (Fig. 3), together with suboptimal concentrations of 15d-PGJ₂ (i.e., 1–2 μM; see Fig. 5). Interestingly, this combination resulted in a significantly greater reduction in [³H]thymidine incorporation than seen with either PPARγ agonist alone (Fig. 6A). The enhanced loss of [³H]thymidine incorporation with 100 μM MEHP and 1–2 μM 15d-PGJ₂ resulted from the induction of apoptosis, as evidenced by a significant increase in a subG₀/G₁ fluorescence peak (Fig. 6B) and an increase in DNA ladder formation (Fig. 6C).

Because apoptosis was induced after cotreatment with 100 μM MEHP and 15d-PGJ₂ (Fig. 6B), a lower MEHP dose, which does not induce apoptosis even in combination with 15d-PGJ₂ (i.e., 75 μM), to apoptosis induction. Therefore, MEHP caused a greater reduction in [³H]thymidine incorporation than with either agent alone (Fig. 6B). The enhanced loss of [³H]thymidine incorporation with 100 μM MEHP and 1–2 μM 15d-PGJ₂ resulted from the induction of apoptosis, as evidenced by a significant increase in a subG₀/G₁ fluorescence peak (Fig. 6B) and an increase in DNA ladder formation (Fig. 6C).
μM), was used to assess p27kip1 up-regulation, a marker for growth inhibition, in the presence of MEHP and 15d-PGJ2. Suboptimal doses of either MEHP (75 μM) or 15d-PGJ2 (0.5–1.0 μM) did not affect p27kip1 expression (Fig. 6D). However, a combination of these PPARγ ligands at these doses significantly increased p27kip1 expression (Fig. 6D), a result consistent with a synergistic effect on growth inhibition. Considering that concentrations of 15d-PGJ2 may be as high as the micromolar range in the bone marrow (43–45), these data suggest that even low exposures to environmental phthalates such as MEHP may have profound effects on bone marrow B cell growth and/or survival.

**Analyses of treatment with MEHP and 15d-PGJ2 or 9-cis-RA: additive vs synergistic effects**

Although previous investigators have referred to the interaction of combinations of PPARγ/RXRα ligands as synergistic (18–21), the methodology used was not sufficient to distinguish true synergy from nonsynergistic, additive effects. The data presented in this study suggested a combinatorial effect between MEHP and 9-cis-RA or 15d-PGJ2. Therefore, we used the isobole method to determine whether the enhancements in biological responses seen with treatment combinations were additive or synergistic. Contour
lines for the response surface of each combination were plotted. These contours represent levels of constant effect in the combination dose space, i.e., isoboles of effect. Isoboles of an asynergistic (i.e., concentration additive) interaction are represented by straight lines with negative slopes. Interactive combinations are manifest as isoboles which curve toward (synergism) or away from (antagonism) the origin (53, 54).

The isoboles of the MEHP plus 15d-PGJ\textsubscript{2} combination are nearly straight lines, indicating an effect that is at least additive effect (Fig. 7A). In contrast, the isoboles of the MEHP plus 9-cis-RA combination are more complex and across most of the concentration range curve toward the origin, indicating a strongly synergistic interaction in this region (Fig. 7B).

**MEHP and 15d-PGJ\textsubscript{2} induce PPAR\textgamma-DNA binding and transcriptional trans-activation**

MEHP has been shown in mouse embryonic carcinoma cells and in PPAR\textgamma-transfected COS cells to be a PPAR\textgamma agonist (15, 16). Previously we have shown that PPAR\textgamma, along with its dimerization partner, RXR\textalpha, are expressed at the pro/pre-B cell stage (31). Furthermore, the synergy between MEHP and 9-cis-RA seen in the present system is consistent with the activation of a PPAR\textgamma-RXR dimer. PPAR\textgamma-specific EMSAs were performed to confirm MEHP- and 15d-PGJ\textsubscript{2}-induced PPAR\textgamma-DNA binding in pro/pre-B cells.

Treatment of BU-11 cells with MEHP or 15d-PGJ\textsubscript{2} increased binding to the PPRE sequence from the acyl-CoA oxidase gene (Fig. 8A). The presence of PPAR\textgamma in the DNA-binding complex was confirmed by a change in the banding pattern similar to that published previously (31) upon inclusion of a PPAR\textgamma-specific Ab (Fig. 8A). In addition, the band could be specifically competed by a 100-fold excess of unlabeled oligonucleotides containing PPREs, but not by DNA of an unrelated sequence. Interestingly, treatment of cells with a combination of suboptimal concentrations of MEHP and 15d-PGJ\textsubscript{2} resulted in PPRE-DNA binding greater than that of either compound alone (Fig. 8A). These results indicate that both MEHP and 15d-PGJ\textsubscript{2} induce PPAR\textgamma-DNA binding in these early B lymphocytes.

To compare MEHP-induced trans-activation with that induced by 15d-PGJ\textsubscript{2}, COS-1 cells were transiently transfected with mouse PPAR\textgamma and with the luciferase reporter plasmid pHDX3-luc, containing three copies of a PPRE derived from the rat enoyl CoA hydratase/3-hydroxyacyl CoA promoter (Fig. 8B), or with the luciferase reporter plasmid pLuc-4A6-880, which included 880 nt of the 5'-flanking DNA of the PPAR\textgamma-responsive rabbit CYP4A6 gene (Fig. 8C). (Transient transfection of BU-11 cells with reporter constructs was not practical because of the high levels of death and the low transfection efficiency seen in these nontransformed cells after either electroporation or FuGene treatment.)

Treatment of transfected COS-1 cells under serum-free conditions with the potent PPAR\textgamma agonist, troglitazone (3 \muM), as a positive control resulted in a 15-fold activation of the CoA reporter and a 6-fold activation of the CYP4A6 reporter (Fig. 8, B and C). MEHP (20 \muM) stimulated a 7-fold activation of the CoA reporter construct and a 3-fold activation of the CYP4A6 reporter (Fig. 8B). Treatment with 1–5 \muM 15d-PGJ\textsubscript{2} resulted in a concentration-dependent increase in activation of the CoA reporter construct, with a 15-fold increase in activation at 5 \muM (Fig. 8B). In contrast, 15d-PGJ\textsubscript{2} exhibited weaker activation of the CYP4A6 reporter, requiring 15 \muM 15d-PGJ\textsubscript{2} for only a 4-fold increase in activity (Fig. 8C). These results show that although MEHP has a lower potency and efficacy in trans-activating the hydroxyacyl CoA gene than 15-dPGJ\textsubscript{2}, MEHP and 15d-PGJ\textsubscript{2} have similar potencies and efficacies in trans-activating the CYP4A6 gene.

**Apoptosis induced by MEHP and 15d-PGJ\textsubscript{2} does not result from inhibition of NF-kB activation**

Previous studies suggested that PPAR\textgamma activation can either enhance (60–62) or down-regulate (36, 37, 63–67) NF-kB activity, and that NF-kB down-regulation results in apoptosis (37). To determine the effect of endogenous and environmental PPAR\textgamma agonists on NF-kB activation, BU-11 cells were treated with 5 \muM 15d-PGJ\textsubscript{2} for 2 h or with 200 \muM MEHP for 8 h. Nuclear proteins were extracted and assayed by EMSA for binding to the upstream kB regulatory element of c-myc. Unlike some studies with 15d-PGJ\textsubscript{2} (36, 63), but consistent with our previous studies with PPAR\textgamma agonists (31), treatment with 15d-PGJ\textsubscript{2} increased NF-kB-DNA binding 1.7-fold (p < 0.01) at 2 h post-treatment (Fig. 9, A and B). The failure to detect a change in binding of the constitutively active Oct-1 transcription factor with its cognate DNA binding element confirmed the specificity of the NF-kB response (data not shown). Similarly, treatment with MEHP for 8 h resulted in a significant (p < 0.01) 1.5-fold increase in NF-kB-DNA binding.

**FIGURE 7.** Isobole analysis of MEHP interactions with 15d-PGJ\textsubscript{2} (A) and 9-cis-RA (B). Suspension cultures of BU-11 cells were treated with ethanol (vehicle, 0.5%), MEHP (25–100 \muM), 15d-PGJ\textsubscript{2} (0.5–2.5 \muM), and/or 9-cis-RA (1–10 \muM) for 48 h. [\textsuperscript{3}H]thymidine incorporation was determined, and contour plots (isobolograms) of the combinatorial effects of MEHP with 15d-PGJ\textsubscript{2} or 9-cis-RA were constructed as described in Materials and Methods. Levels shown are fractional responses of the Vh-Vh cell. Circles indicate locations of data points from three experiments. Contours are linear interpolation between points.
Supershift assays then were used to identify the subunits in the active NF-κB complex. An Ab to p50 supershifted both the faster and slower migrating κB complexes (indicated by single and double arrows, respectively; Fig. 9C), whereas p65/RelA- and c-Rel-specific Abs significantly decreased the slower migrating NF-κB band (double arrows above the dashed line). These results are similar to those obtained with the synthetic PPARγ ligands, ciglitazone and GW7845 (31). In general, these results indicate that, unlike apoptosis induced with other environmental chemicals (52), apoptosis induced in developing B cells by natural or environmental PPARγ ligands is not mediated by NF-κB down-regulation.

Discussion

Humans receive significant ambient daily exposures to phthalates and substantially higher acute exposures during medical procedures (68). It is increasingly apparent that these environmental phthalate exposures may have significant biological consequences. For example, exposure to one phthalate, DEHP, results in hepatocarcinogenesis (8) and renal, ovarian, testicular, and developmental toxicity (9–12). Similarly, MEHP, the active metabolite of DEHP, suppresses aromatase expression in a model of reproductive toxicity (13) and induces Fas-dependent
apoptosis in testis (10). Much of this toxicity is mediated by PPARγ or PPARγ together with PPARα (8, 9, 11, 26, 27).

The facts that phthalate ester metabolites are PPARγ agonists and that PPARγ agonist drugs induce lymphocyte apoptosis suggest that phthalate esters may target the immune system as well as those organ systems noted above. Several studies support this conclusion. Microarray analyses of liver from DEHP-treated C57BL/6 mice indicates down-regulation of complement components (69). High doses of MEHP and other monophthalates suppress OVA-specific Ab production in BALB/cJ mice (70). DEHP treatment of C57BL/6 mice induces severe thymic and splenic atrophy (71). In the spleen, treatment with another peroxisome proliferator, perfluoro-octanoic acid, decreases the total number of CD19+ B cells by 86% and substantially reduces the percentage of splenic B cells (71). However, it is not clear whether this decrease is due to direct effects on mature B cell populations and/or on their development from bone marrow-derived precursors.

In this study we show for the first time that cells in the developing immune system indeed are sensitive to an environmental phthalate ester. MEHP both induces apoptosis and suppresses cell proliferation in developing bone marrow B cells. Considerable evidence supports a role for PPARγ in these processes: 1) pro/pre-B cells express PPARγ and RXRα (31); 2) cotreatment with MEHP and an RXRα agonist synergistically decreases cell growth and increases the incidence of apoptosis (Figs. 2–4 and 7); 3) MEHP induces binding of PPARγ complexes to PPAR-specific DNA response elements (Fig. 8); and 4) MEHP induces PPRE-driven reporter activity (Fig. 8). The role of PPARγ in MEHP-induced pro/pre-B cell apoptosis is supported further by the fact that BU-11 cells are susceptible to apoptosis induced by synthetic PPARγ agonists (31). In addition, MEHP-induced apoptosis of U937 monocytic leukemia cells has been shown to be PPARγ dependent (72). However, these results do not preclude the possibility that PPARα-mediated processes contribute to the described effects (37).

Interestingly, cell cycle arrest occurred at MEHP concentrations lower than those required to induce apoptosis, effectively separating the two events. That is, no significant apoptosis induction was seen at 100 μM MEHP in BU-11 cells (Fig. 3), whereas 100 μM MEHP significantly reduced the percentage of cells in S/G2/M (Fig. 4). Similarly, a reduction in [3H]thymidine, but no apoptosis induction, was seen in primary pro-B cells after exposure to 10 μM MEHP (Fig. 1). The increase in expression of p27Kip1 in BU-11 cells suggests a role for this protein in MEHP-induced cell cycle arrest. Not surprisingly, cell cycle arrest is required for the PPARγ-mediated process of adipocyte terminal differentiation (73). Similarly, synthetic and natural PPARγ agonists can induce cell cycle arrest. For example, troglitazone induces p53, p27Kip1, p21Waf1, and Rb, while reducing cyclin D1 expression and cyclin-dependent kinase activity, resulting in G1 arrest of hepatoma cells (74, 75). Similarly, troglitazone induces p27Kip1 expression and G1 cell cycle arrest in pancreatic carcinoma cells (76). Ciglitazone and 15d-PGJ2 decrease cyclin D1 expression by enhancing its proteasome-dependent degradation, resulting in G1 cell cycle arrest in MCF-7 breast cancer cells (77). Finally, ectopic expression of PPARγ in combination with pioglitazone treatment result in an early increase in p27Kip1 and p21Waf1 expression, followed by an increase in p18 expression and a loss of p21Waf1 in fibroblasts (73). Collectively, these studies indicate that MEHP and other environmental PPARγ agonists may take advantage of a naturally occurring cell cycle arrest program in several cell types.

The analyses performed in this study suggest a strongly synergistic interaction between MEHP and 9-cis-RA in the induction of apoptosis (Fig. 7). Although synergistic induction of early B cell apoptosis and growth arrest by a combination of an environmental

![FIGURE 9](image-url)
PPARγ agonist and an RXRα activator has not been shown before, considerable precedent exists for increased signaling in other systems when both receptors are activated. The PPARγ/RXRα heterodimer is known as a permissive heterodimer in which RXRα ligands alone can activate transcription by the heterodimer (78). Cotreatment with ligands for both PPARγ and RXRα results in an increase in PPARγ-dependent transactivation of reporter genes, adipocyte differentiation in cultured cells (21), and differentiation of liposarcomas in vivo (79). The combinatorial effect results from increased recruitment of coactivators and an RXRα-dependent conformational change in PPARγ (21).

Perhaps of still greater immunological significance is the effect seen when pro/pre-B cells were exposed to a combination of MEHP and an endogenous PPARγ ligand, 15d-PGJ2 (Fig. 6). For example, cotreatment of pro/pre-B cells with 1–2 μM 15d-PGJ2 and MEHP significantly reduced [3H]thymidine incorporation and enhanced the growth arrest seen with MEHP alone. Furthermore, pro/pre-B cells underwent cell cycle arrest, but not apoptosis when treated with 1–2 μM 15d-PGJ2, or 100 μM MEHP. However, when exposed to a combination of 2 μM 15d-PGJ2 and 100 μM MEHP, considerable apoptosis was evident. Isobole analysis showed that this combinatorial effect was at least additive (Fig 7A). Importantly, 15d-PGJ2 and its precursor, PGD2, are found at high concentrations in bone marrow, potentially reaching local concentrations in the micromolar range (43–45). These results suggest that B cells in the bone marrow microenvironment may be particularly susceptible to phthalate-induced toxicity. Indeed, because of the high background concentration of 15d-PGJ2 in the bone marrow, the concentration of MEHP required to cause toxic effects in vivo may be significantly lower than those extrapolated from in vitro studies in which the effects of MEHP or other PPARγ agonists were studied in the absence of exogenous 15d-PGJ2.

In summary, the results presented in this study demonstrate that an environmentally ubiquitous pollutant, DEHP/MEHP, is toxic to early bone marrow B cells and suggest that this immunotoxicity is at least in part PPARγ dependent. The developing B cell compartment is known to be exquisitely sensitive to other environmental toxins, such as polycyclic aromatic hydrocarbons (49, 57, 58). The sensitivity of primary bone marrow B cells is indicated by their significant response to concentrations of MEHP as low as 10 μM, a concentration 10-fold lower than that required to effect a response in the pro/pre-B cell line. Acute human exposure to DEHP/MEHP from a blood transfusion alone can be as high as 3–4 mg/kg for an adult weighing 70 kg (6), and concentrations in blood can range from 50–350 μM (7). Furthermore, the total daily ambient phthalate ester exposure of humans may reach 500 μg/kg/day (4). Considering that many phthalate esters are agonists for PPARs (13–16), that bone marrow contains high levels of a naturally occurring PG PPARγ agonist, and that primary bone marrow B cells have a relatively low threshold for phthalate-induced effects, the cumulative exposure to multiple phthalate esters may have significant consequences to developing human B lymphocytes. Further research is required to delineate the signaling pathways responsible for PPARγ agonist-induced B cells apoptosis.

References
Juge-Abury, C., A. Pernin, T. Favex, A. Burger, W. Wahl, C. A. Meier, and
Gosset, P., A.-S. Charbonnier, P. Delerive, J. Fontaine, B. Staels, J. Pestel, A.-B.
Pharmacol. Rev. 41:93
Berenbaum, M. C. 1989. What is synergy?

Gosset, P., A.-S. Charbonnier, P. Delerive, J. Fontaine, B. Staels, J. Pestel, A.-B.

Forman, B. M., P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and
R. M. Evans. 1995. 15-Deoxy-
Prostaglandins Leukotrienes Essen. Fatty Acids

Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-


Matsupil, W., T. Okomura, N. Takahashi, T. Obara, and Y. Kohgo. 2000. Activ-
ation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase in p27 Kipl in human pancreatic carcinoma cells. Cancer Res. 60:3553.


tiation of human liposarcoma cells induced by ligands for peroxisome prolifera-